Table 2. Peritoneal dialysis-related characteristics in EPS patients.
| PD characteristic | Total (N = 58)b | Severe group (n = 23) | Mild/moderate group (n = 34) | P valuec |
|---|---|---|---|---|
| PD duration, years | 13.2 ± 3.8 | 13.0 ± 3.3 | 13.4 ± 4.1 | 0.7 |
| PD modality, CAPD/APDa | 52/6 | 21/2 | 30 /4 | 1.0 |
| Peritoneal transport category | ||||
| High average/High | 51 (93) | 19 (95) | 31 (91) | 1.0 |
| PD dose, L/day | 9.2 ± 2.3 | 9.1 ± 2.2 | 9.0 ± 2.1 | 0.8 |
| Icodextrin use | 50 (89) | 19 (86) | 30 (91) | 0.7 |
| Duration of icodextrin use, months | 78.6 (22.0, 103.4) | 67.0 (33.0, 94.0) | 88.3 (17.5, 104.1) | 0.9 |
| Renal Weekly Kt/V | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0.9 |
| Peritonitis rate before EPS, episode/patient-year | 0.08 (0, 0.21) | 0.07 (0, 0.20) | 0.10 (0.05, 0.37) | 0.1 |
Data are presented as means ± SDs (normally distributed data), medians (interquartile ranges) (non-normally distributed data), or numbers (percentages).
aPD modality at EPS diagnosis: automatic peritoneal dialysis (APD) or continuous ambulatory peritoneal dialysis (CAPD).
bOne patient with unknown cause of death was not included in either group.
cP for severe group vs. mild/moderate group.